Refine by
Post Traumatic Stress Disorder Ptsd Articles & Analysis
24 news found
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
The formulated product is branded as Mentabinol®, which addresses various psychiatric disorders. Acute THC consumption can trigger paranoid thoughts in vulnerable individuals. ...
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
Amin Kassam, the CEO of Neeka, a true pioneer in novel surgical procedures, neurological disorders, and innovative health solutions, led the creation and development of the Neeka platform. ...
The library of compounds can be selected to target (personalize) the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate (OUD), and cocaine addiction, alcoholism (AUD), post-traumatic stress disorder (PTSD), ...
Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.com CanaQuest has further enhanced the formulation and delivery format for maximum ...
Laviolette and his dedicated team of 13 scientists at Western University focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and addiction. www.laviolettelab.com CanaQuest has further enhanced the formulation and delivery format for maximum ...
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain, an applied, integrative neuroscience company, to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological ...
If a woman has previously been diagnosed with panic disorder or obsessive-compulsive disorder, then they are at risk of the disorder reoccurring in the postpartum period. These disorders are also frequently co-morbid with PPD and may worsen the prognosis. Birth related post traumatic ...
Italian-based Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Bexson Biomedical, Inc., a research stage company developing subcutaneous therapies for pain management and mental health disorders, announced today that they have signed an agreement expanding their ...
The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health technology companies chosen for their innovative technologies and patient impact. 2021 is the sixth year for the Rosenman Innovator selection cycle, which has the goal of identifying promising companies seeking funding from seed stage to Series A. The number of companies ...
SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health technology companies chosen for their innovative technologies and patient impact. 2021 is the sixth year for the Rosenman Innovator selection cycle, which has the goal of identifying promising companies seeking funding from seed ...
Results of its potential effect on anxiety, depression, PTSD, and schizophrenia have been statistically significant. Our evidence also found that this formulation targeted a specific nuclear cellular receptor involved in anti-inflammatory mechanisms indicating that this formula may also treat inflammatory disorders. ...
Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat. No. 10,973,780, describing pharmaceutical formulations and treatment methods including the company's BB106 ketamine therapy. Bexson believes the new ...
Steven Laviolette, who has decades of research experience focused on novel pharmacotherapies addressing anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder ...
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced it has been awarded the International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma, United Kingdom, a ...
The Company’s research is focused on the use of cannabinoids for the development of novel pharmacotherapies for mental health, such as anxiety, depression, addiction, schizophrenia, and Post Traumatic Stress Disorder “PTSD”. CanaQuest has identified the regulatory pathways to obtain Drug ...
Their research focuses on using cannabinoids for the development of novel pharmacotherapies to address anxiety, depression, addiction, schizophrenia and Post Traumatic Stress Disorder (PTSD). Treena Reilkoff, a Trauma Informed Mediator and Facilitator with the CCDRC stated, “We are pleased to have the ...
The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD", including addiction.The Company is the industry partner for research and product development with Dr. ...